Nanogen Moves Ahead With New Microarray System After FDA Warning
This article was originally published in The Gray Sheet
Executive Summary
A warning letter issued to San Diego-based Nanogen Aug. 11 highlights the continued focus of the agency's in vitro diagnostic regulators on analyte-specific reagents (ASRs)
You may also be interested in...
Test Makers Have One Year To Comply With New ASR Guidelines
Diagnostic test makers will have until September 2008 to comply with newly clarified FDA policies for analyte specific reagents
Test Makers Have One Year To Comply With New ASR Guidelines
Diagnostic test makers will have until September 2008 to comply with newly clarified FDA policies for analyte specific reagents
Nanochip 400 510(k)
Nanogen files a 510(k) for its Cystic Fibrosis Kit and Nanochip 400 microarray system for carrier testing in adults, as an aid to newborn screening and in confirmatory diagnostic testing in newborns and children. The genetic assay uses an automated multiplexing platform that tests for 23 mutations, which account for 90% of U.S. cystic fibrosis cases. In August 2005, the firm received one of several letters from FDA to in vitro diagnostic test makers warning that its tests were "integrated" diagnostic devices that require 510(k) clearance (1"The Gray Sheet" Aug. 22, 2005, p. 9)...